Cancer-related Fatigue During Maintenance Immunotherapy for Non-small Cell Lung Cancer (NSCLC): a Qualitative Study

Inclusion criteria

• ≥ 18 years of age at the time of consent.
• Must be able to speak, read, and understand English.
• Participants diagnosed with NSCLC, and:
• have advanced/metastatic disease who are currently receiving immunotherapy monotherapy, or
• have locally advanced disease who are currently receiving immunotherapy monotherapy after completing thoracic radiation therapy, or
• who underwent resection and are currently receiving immunotherapy monotherapy after completing all other perioperative treatment
• Immunotherapy planned to continue for at least three months after the time of study enrollment (to ensure participant remains on IO long enough to obtain study assessments)
• Have completed at least two cycles of immunotherapy.
• Self-reported cancer-related fatigued that impacts daily function.

Exclusion criteria

• Participants who have received a dose of chemotherapy (including maintenance pemetrexed) within the past 3 months
• Participants who have received radiation therapy within the past 3 months. Note: a short course of palliative radiation therapy within up to 20 Gy and up to 5 fractions is permissible.
• Diagnosis of dementia.
• Anemia Hgb \<10 g/dL.
• Sarcopenia which is being pharmacologically treated with a prescribed appetite stimulant (e.g., megestrol).
• Untreated hypothyroidism.
• Symptomatic heart failure.
• Oxygen dependent lung disease.
• Cognitively unable to complete interviews per investigator.